PreprintArticleVersion 1This version is not peer-reviewed
The Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Drug Resistance Testing for Pre-Treated Patients
Version 1
: Received: 29 September 2024 / Approved: 29 September 2024 / Online: 30 September 2024 (15:12:36 CEST)
How to cite:
Zhou, Y.; Ouyang, F.; Liu, X.; Lu, J.; Hu, H.; Sun, Q.; Yang, H. The Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Drug Resistance Testing for Pre-Treated Patients. Preprints2024, 2024092356. https://doi.org/10.20944/preprints202409.2356.v1
Zhou, Y.; Ouyang, F.; Liu, X.; Lu, J.; Hu, H.; Sun, Q.; Yang, H. The Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Drug Resistance Testing for Pre-Treated Patients. Preprints 2024, 2024092356. https://doi.org/10.20944/preprints202409.2356.v1
Zhou, Y.; Ouyang, F.; Liu, X.; Lu, J.; Hu, H.; Sun, Q.; Yang, H. The Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Drug Resistance Testing for Pre-Treated Patients. Preprints2024, 2024092356. https://doi.org/10.20944/preprints202409.2356.v1
APA Style
Zhou, Y., Ouyang, F., Liu, X., Lu, J., Hu, H., Sun, Q., & Yang, H. (2024). The Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Drug Resistance Testing for Pre-Treated Patients. Preprints. https://doi.org/10.20944/preprints202409.2356.v1
Chicago/Turabian Style
Zhou, Y., Qi Sun and Haitao Yang. 2024 "The Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Drug Resistance Testing for Pre-Treated Patients" Preprints. https://doi.org/10.20944/preprints202409.2356.v1
Abstract
Next-generation sequencing(NGS) for HIV drug resistance(DR) testing has an increasing number of applications for detection of Low-abundance drug resistant variants(LA-DRVs) as its features of quasispecies. However there is less information on detection performance in DR detection with NGS.To determine the feasibility of NGS technology in LA-DRVs detection for HIV-1 pre-treated patients.In this study,80 pre-treated patients’ samples accepted both NGS and Sanger sequencing(SS) in HIV-1 drug resistance testing. The results show that NGS presents higher sensitivity in mutation sites discovery at 5% threshold. NGS shows a satisfactory consistency comparing with SS in both protease inhibitors(PIs) and Integrase inhibitor(INSTIs), more than 90%. But worse consistency in Nucleotide reverse transcriptase inhibitors(NRTIs), only ranging from 61.25%-87.50%. The consistency of Non-nucleotide reverse transcriptase inhibitors(NNRTIs) between NGS and SS was around 85%. NGS shows the highest sensitivity of 91.3% at 5% threshold. The application of NGS technology in HIV-1 genotype resistance detection in different populations infected with HIV needs more documents and to be confirm further.
Keywords
Next-generation sequencing; HIV-1 drug resistance; consistency comparison
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
